论文部分内容阅读
目的:观察雷替曲噻联合羟基喜树碱和顺铂治疗晚期结直肠癌的安全性,探索治疗晚期结直肠癌的有效方法。方法:雷替曲噻3mg.m-2静滴15min,第1天;羟基喜树碱6mg.m-2,静滴第1～5天;顺铂10mg.m-2静滴第1～5天。每3周重复。结果:在6例复治患者中,5例至少进行了2个周期化疗,可评价疗效,其中,部分缓解(PR)1例,微效(MR)1例,稳定(SD)3例。与研究方案相关的毒副反应为:I～Ⅲ度恶心/呕吐3例,腹泻1例,Ⅲ度便秘1例;I度血总胆红素升高和谷丙转氨酶升高各1例;此外还有周围神经毒性1例,表现为早搏的心脏毒性1例。有1例女性患者出现Ⅲ度血小板下降,经治疗后恢复。未见Ⅳ级毒副反应,无治疗相关死亡。结论:雷替曲噻联合羟基喜树碱和顺铂治疗晚期结直肠癌安全性好,值得进一步观察疗效。
Objective: To observe the safety of raltitrexed combined with hydroxycamptothecin and cisplatin in the treatment of advanced colorectal cancer, and to explore an effective method for the treatment of advanced colorectal cancer. Methods: Rituxetine 3mg.m-2 intravenous infusion 15min, the first day; hydroxycamptothecin 6mg.m-2, intravenous drip 1 ~ 5 days; cisplatin 10mg.m-2 intravenous drip 1 ~ 5 day. Repeat every 3 weeks. Results: Of the 6 retreatment patients, 5 patients were treated with at least 2 cycles of chemotherapy. The results were as follows: partial response (PR) 1, microeffect (MR) 1, and stable (SD) 3 patients. Toxicities and side effects associated with the study protocol were: 3 cases of grade Ⅲ-Ⅲ nausea / vomiting, 1 case of diarrhea and 1 case of Ⅲ degree constipation; 1 case of elevated serum total bilirubin and elevated alanine aminotransferase in 1 case; There are 1 cases of peripheral neurotoxicity, manifested as premature beats of cardiotoxicity in 1 case. A female patient had Grade III thrombocytopenia and recovered after treatment. No grade Ⅳ toxicity, no treatment-related death. Conclusion: Retivatriptan combined with hydroxycamptothecin and cisplatin in the treatment of advanced colorectal cancer is safe and worth further observation.